By undertaking additional analysis of clinical data, study results can yield potentially valuable insights beyond a study's primary objective.
Post-hoc analyses of study data can reveal additional insights surrounding a study's drug or treatment. Meanwhile, using multiple data layers can tease out additional insights surrounding drug or treatment effects on particular subsets of a study's population.
During Arena International Event Group's 2026 Outsourcing in Clinical Trials Southern California conference (OCT SoCal), Clinical Trials Arena spoke with Craig Chambliss, CEO of Neurelis, to learn more about scrutinising trial data beyond a study's original objective to support further evidence generation.
Listen to the full episode below:
